Hamburg, Germany

Klaus Glänzer

This inventor holds 2 USPTO granted patents and 2 EPO patents. Top assignee: Helm Ag. Active years: 2010.



Average Co-Inventor Count = 1.5

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2010

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Klaus Glänzer: Innovator in Pharmaceutical Chemistry

Introduction

Klaus Glänzer is a prominent inventor based in Hamburg, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative drug formulations. With a focus on improving the efficacy and stability of medications, Glänzer has secured a total of 2 patents throughout his career.

Latest Patents

Among his latest patents are two notable inventions. The first is titled "Amorphous aripiprazole and process for the preparation thereof," which involves morphologically stabilized amorphous aripiprazole and the process for preparing the same. The second patent, "Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof," relates to an adsorbate that includes an adsorbent and bicalutamide adsorbed on said adsorbent, along with a process for preparing it and a pharmaceutical composition.

Career Highlights

Klaus Glänzer is currently associated with Helm AG, where he continues to push the boundaries of pharmaceutical innovation. His work has been instrumental in developing new therapeutic options that enhance patient outcomes.

Collaborations

Some of his notable coworkers include Katja Stritzke and Uwe Löffler, who have collaborated with him on various projects within the company.

Conclusion

Klaus Glänzer's contributions to pharmaceutical chemistry through his patents and work at Helm AG highlight his commitment to advancing medical science. His innovative approaches continue to pave the way for new treatments and improved drug formulations.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…